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Heterotrimeric G-proteinThe 5-HT7 receptor is the most recently described member of the serotonin receptor family. This receptor is
mainly expressed in the thalamus, hypothalamus as well as in the hippocampus and cortex. In the present
study, we demonstrate that the mouse 5-hydroxytryptamine 5-HT7(a) receptor undergoes post-translational
modiﬁcation by the palmitate, which is covalently attached to the protein through a thioester-type bond.
Analysis of protein-bound fatty acids revealed that the 5-HT7(a) receptor predominantly contains palmitic
acid. Labelling experiments performed in the presence of agonists show that the 5-HT7(a) receptor is
dynamically palmitoylated in an agonist-dependent manner and that previously synthesized receptors may
be subjected to repeated cycles of palmitoylation/depalmitoylation. Mutation analysis revealed that cysteine
residues 404 and 438/441 located in the C-terminal receptor domain are the main palmitoylation sites
responsible for the attachment of 90% of the receptor-bound palmitate. Analysis of acylation-deﬁcient
mutants revealed that non-palmitoylated 5-HT7(a) receptors were indistinguishable from the wild-type for
their ability to interact with Gs- and G12-proteins after agonist stimulation. However, mutation of the
proximal palmitoylation site Cys404-Ser (either alone or in combination with Cys438/441-Ser) signiﬁcantly
increased the agonist-independent, Gs-mediated constitutive 5-HT7(a) receptor activity, while the activation
of Gα12-protein was not affected. This demonstrates a functional importance of 5-HT7(a) dynamic
palmitoylation for the ﬁne tuning of receptor-mediated signaling.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Five-hydroxytryptamine (5-HT or serotonin) is a modulating
neurotransmitter involved in a wide range of physiological and
pathological functions within the central nervous system and at the
periphery. Serotonin operates by activating a large family of speciﬁc
receptors, which are divided into seven distinct classes based on their
structural and functional characteristics [1]. With the exception of the
5-HT3 receptor, which is a ligand-gated ion channel, all the other
serotonin receptors belong to the superfamily of G-protein coupled
receptors (GPCRs) that activate multiple heterotrimeric G-proteins [2].
The 5-HT7 receptor is one of themost recently describedmembers of
this receptor family, which has been cloned in several species, including
mouse, rat and humans [1,3]. In situmRNA hybridization, immunolabel-
ling and radioligand binding studies demonstrated that the highestx: +1 0511 532 8302.
e (E. Ponimaskin).
ll rights reserved.receptor density occurs in the thalamus and hypothalamus, and a
signiﬁcant density is also observed in the hippocampus and cortex [3].
The 5-HT7 receptor stimulates cAMP formation by activating adenylyl
cyclases via a stimulatory Gs-protein, which also leads to Ras-dependent
activation of the extracellular signal-regulated kinases (ERK) [4]. In
addition, the 5-HT7 receptor is coupled to the G12-protein to activate
small GTPases of the Rho family, which leads to enhanced neurite
outgrowth [5]. The 5-HT7 receptor is associated with a number of
physiological and pathophysiological responses, including serotonin-
induced phase shifting of the circadian rhythm [6] and the age-
dependent changes of the circadian timing [7]. A large amount of
experimental data suggests that 5-HT7 receptors are also involved in
sleep induction andhypothermia, and suchobservationswere conﬁrmed
in a mouse strain with a disrupted 5-HT7 gene [8,9]. The high receptor
afﬁnity to several migraine prophylactic drugs has suggested that 5-HT7
receptors may also be involved in the development of migraine [10].
Signaling proteins often undergo post-translational modiﬁcations.
One of these modiﬁcations is a covalent attachment of long chain
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the protein via a labile thioester linkage (palmitoylation). With the
ﬁnding that palmitoylation is a dynamic process, it is now widely
accepted that repeated cycles of palmitoylation and depalmitoylation
may be involved in regulating signaling processes in cells [11–13].
Palmitoylation also represents a common post-translational
modiﬁcation of GPCRs [14,15]. Moreover, palmitoylation of several
GPCRs has been shown to play a central role in the regulation of their
functions, determining the efﬁciency and selectivity of G-protein
coupling, receptor phosphorylation and desensitization, endocytosis
and transport to the plasma membrane [16–18]. Recently we have
shown that two members of the serotonin receptor family, 5-HT4(a)
and 5-HT1A receptors, are modiﬁed by palmitic acid [19–21].
Palmitoylation of the 5-HT4(a) receptor is modiﬁed by agonists and
involved in the modulation of constitutive receptor activity [22]. In
contrast, the efﬁciency of palmitoylation of the 5-HT1A receptor was
not affected by the agonist. Moreover, mutation of palmitoylated
cysteine residues in the 5-HT1A receptor abolished coupling of the
receptor to Gi-protein and impaired inhibition of adenylyl cyclase
activity. This indicates that palmitoylation of 5-HT1A receptor is
critical for effective Gi-protein-mediated signaling [20].
In the present study, we demonstrate thatmouse 5-HT7(a) receptor
is post-translationally modiﬁed with a covalently bound palmitic acid.
We also identiﬁed the potential palmitoylation sites and show that 5-
HT7(a) receptor palmitoylation is not restricted to the receptor C-
terminal domain. Using acylation-deﬁcient mutants, we demonstrat-
ed a functional signiﬁcance of 5-HT7(a) receptor palmitoylation for the
regulation of receptor constitutive activity mediated by the Gs- but
not by the G12-protein.
2. Materials and methods
2.1. Materials
[9,10-3H(N)]palmitic acid (30–60 Ci/mmol), [35S]GTPγS (1300 Ci/
mmol) and Tran[35S]-label (1000 Ci/mmol) were purchased from
Hartmann Analytic GmbH (Germany). [3H]5-hydroxytryptamine cre-
atinine sulfate, ECL Western blotting analysis system and peroxidase-
conjugated secondary antibodies were purchased from Amersham
Biosciences (Germany). Enzymes used in molecular cloning were
obtained from New England Biolab (Germany). Protein A-Sepharose
CL-4B beads, serotonin and clozapine were from Sigma. TC-100 insect
cell and DMEM medium, Cellfectin and LipofectAMINE 2000 reagents
were purchased from Invitrogen (Germany). The receptor antagonist
SB269970 was purchased from Tocris (Germany). Cell culture dishes
were obtained from Nunc (Germany). Oligonucleotide primers were
synthesized by Invitrogen. AmpliTaq DNA polymerase was from
PerkinElmer Life Sciences (Germany). Anti-myc epitope antibodies
were purchased from Santa Cruz Biotechnology (Germany).
2.2. Recombinant DNA procedures
All basic DNA procedures were performed as described by
Sambrook and co-workers [23]. The mice 5-HT7(a) cDNA was kindly
provided by Dr. Isabel Bermudez (School of Biological and Molecular
Science, Oxford). The 5-HT7(a) cDNA was ampliﬁed with speciﬁc
primers c-Myc-7a-sense (5′- CCA AGC TTC GCC ACC ATG GAA CAA
AAA CTC ATC TCA GAA GAG GAT CTG ATG GAC GTT AAC AGC AGC -3′)
and 7a-antisense (5′-GTG GTA TGG CTC ATT ATG ATC C -3′) to create
11–amino acid c-Myc tag (MEQKRISEEDL) at the N-terminus of the
receptor. The PCR fragment was ligated to the HindIII site of the
multiple cloning sites of pTracer-CMV2 or pFastBac plasmid (Invitro-
gen). Site-directedmutagenesis of the epitope-tagged 5-HT7(a) receptor
with the substitution of serine for cysteine at position 404, 438 and/or
441 was performed by overlap extension PCR technique using an
oligonucleotide containing the mutation(s) corresponding to the abovesubstitutions. All mutants were veriﬁed by dideoxy DNA sequencing of
the ﬁnal plasmid. The recombinant baculoviruses encoding for 5-HT7(a)
wild-type and acylation-deﬁcient mutants were constructed, puriﬁed
and ampliﬁed as described previously [24].
2.3. Metabolic labelling and immunoprecipitation
Spodoptera frugiperda Sf.9 cells were grown in TC-100 medium
supplemented with 10% fetal calf serum (FCS) and 1% penicillin/
streptomycin (complete TC-100). For expression, Sf.9 cells (1.5×106)
grown in 35 mm dishes were infected with recombinant baculovirus
encoding for myc-tagged 5-HT7(a) receptor at a multiplicity of
infection (MOI) of 10 p.f.u. per cell. After 48-h incubation, Sf.9 cells
were labelled with Tran[35S]-label (50 μCi/ml) or [3H]-palmitic acid
(300 μCi/ml, 30–60 Ci/mmol) for the time periods indicated in ﬁgure
legends. In some experiments, serotonin, SB269970 or clozapine was
added to the ﬁnal concentrations as indicated in ﬁgure legends. To
block protein synthesis, cycloheximide (50 μg/ml) was added 10 min
prior to incubation with [3H]-palmitate or Tran[35S]-label. After
labelling, cells were washed once with ice-cold PBS (140 mM NaCl,
3 mM KCl, 2 mM KH2PO4, 6 mM Na2HPO4, pH 7.4) and lysed in 600 μl
of NTEP buffer (0.5% Nonidet P-40, 150 mM NaCl, 50 mM Tris–HCl,
5 mM EDTA, 10 mM iodoacetamide, 1 mM phenylmethylsulfonyl
ﬂuoride, pH 7.9). Insoluble material was removed by centrifugation,
and anti-myc antibodies were added to the resulting supernatant at a
dilution of 1:60. After overnight agitation at 4 °C, 30 μl of protein A-
Sepharose CL-4B was added, and samples were incubated under
gentle rocking for 2 h. The pellet was washed with ice-cold NTEP
buffer, and the immunocomplexes were released from the beads by
incubation for 30min at 37 °C in non-reducing electrophoresis sample
buffer (62.5 mM Tris–HCl containing 20% glycerol, 6% SDS and 0.002%
bromphenol blue, pH 6.8). Radiolabelled polypeptides were analyzed
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) on 12% acrylamide gels under non-reducing condition and
visualized by ﬂuorography using Kodak X-Omat AR ﬁlms. Densito-
metric analysis of ﬂuorograms was performed by Gel-Pro Analyzer
Version 3.1 Software.
2.4. Hydroxylamine treatment and fatty acid analysis
SDS-gels containing [3H]-palmitate-labelled 5-HT7(a) receptors
were treated overnight under gentle agitation with 1 M hydroxyl-
amine (pH 7.5) or 1 M Tris (pH 7.5), washed in water and incubated
for 30 min in dimethyl sulfoxide to wash out cleaved fatty acids. The
gels were then soaked in water twice for 30 min to remove DMSO and
processed to ﬂuorography.
For the fatty acid analysis, [3H]-palmitate-labelled 5-HT7(a)
receptor was immunoprecipitated from infected Sf.9 cells with anti-
myc antibody and subjected to SDS–PAGE. The band corresponding to
the 5-HT7(a) receptor was excised and fatty acids were cleaved by
treatment of the dried gel slices with 6 N HCl for 16 h at 110 °C. Fatty
acids were extracted with hexane and separated into individual fatty
acid species by thin layer chromatography on RP-18 TLC plates
(Merck) using acetonitrile/acetic acid (1:1, v/v) as solvent. Radio-
labelled fatty acids were visualized by ﬂuorography. For identiﬁcation
of individual fatty acid species, radiolabelled markers ([3H]-myristate,
[3H]-palmitate and [3H]-stearate) were run on the same plate.
2.5. Assay for [35S]GTPγS binding in membrane of Sf.9 cells
Agonist-promoted binding of [35S]guanosine 5-(3-O-thio)triphos-
phate to different G-proteins caused by stimulation of 5-HT7(a)
receptors was performed as described previously [25]. Brieﬂy,
membranes from Sf.9 cells expressing the 5-HT7(a) receptor wild-
type or acylation-deﬁcient mutants and G-protein alpha subunits (Gi,
Gs, Gq, G12 and G13) together with Gβ1γ2 subunits were re-suspended
1648 E. Kvachnina et al. / Biochimica et Biophysica Acta 1793 (2009) 1646–1655in Tris–HCl (50 mM, pH 7.4) containing 2 mM EDTA, 100 mM NaCl,
3 mMMgCl2 and 1 μM GDP. After adding [35S]GTPγS (1300 Ci/mmol)
to a ﬁnal concentration of 30 nM, samples were incubated for 5 min at
30 °C in the presence or absence of 1 μM serotonin. The reaction was
terminated by adding Tris–HCl (50 mM, pH 7.5) containing 20 mM
MgCl2, 150 mMNaCl, 0.5% Nonidet P-40, 200 μg/ml aprotinin, 100 μM
GDP and 100 μM GTP for 30 min on ice. Samples were agitated for 1 h
at 4 °C after addition of 10% suspension of protein A-Sepharose and
antibodies directed against appropriate Gα-subunits. Immunopreci-
pitates were washed and boiled in 0.5 ml of 0.5% SDS, and
radioactivity was measured by scintillation counting.
2.6. Culturing and transfection of COS-7 cells
COS-7 cells were grown in Dulbecco's modiﬁed Eagle's medium
(DMEM) containing 10% fetal calf serum (FCS) and 1% penicillin/
streptomycin at 37 °C under 5% CO2. The cDNA encoding for the
wild-type or mutated 5-HT7(a) receptors in pTracer-CMV2 plasmid
was introduced into COS-7 cells by electroporation. Brieﬂy, cells
were trypsinized, centrifuged and re-suspended in EP buffer (50 mM
K2HPO4, 20 mM CH3CO2K, 20 mM KOH, 26.7 mM MgSO4, pH 7.4)
containing 25–2000 ng of receptor cDNA. The total amount of DNA
was kept constant at 15 μg per transfection using pTracer vector.
After 15-min exposure at room temperature, 300 μl of cell
suspension (107 cells) were transferred to a 0.4 ml electroporation
cuvette (BioRad) and pulsed using a Gene-pulser apparatus (setting
1000 μfarads, 280 V). Afterwards, cells were diluted in DMEM (106
cells/ml) containing 10% dialyzed fetal bovine serum (dFBS) and
plated on 15 cm dishes.
2.7. Determination of cAMP production in intact COS-7 cells
Six hours after transfection, the complete medium was exchanged
by DMEM without dFBS containing 2 μCi [3H]-adenine per ml to label
the ATP pool. To measure cyclic AMP accumulation, medium
containing [3H]-adenine was replaced after overnight incubation by
900 μl of HBS, containing 10% pargyline, 10% ascorbate and 1.6 mM
phosphodiesterase inhibitor RO-20-1724 and 100 μl of either
serotonin (agonist) at concentration range from 1 nM to 1 mM or
clozapine (inverse agonist) at 1 μM. After 10-min incubation at 37 °C,
reaction was stopped by 1 ml of ice-cold 5% three chloro acetic acid
(TCA). Cells were scraped and 100 μl of 200 mMmix of ATP and cAMP
was added prior to centrifugation at 1700 rpm for 10min. Intracellular
cAMP levels were determined by measuring the conversion of the
[3H]-adenine nucleotide precursor [3H]ATP to [3H]cAMP as previously
described [26].
2.8. Assay for [3H]-5-HT binding in membrane of COS-7 cells
Membranes were prepared from transiently transfected COS-7
cells plated on 15 cm dishes and grown in DMEM supplemented with
10% dFBS as previously described [22]. The cells were harvested in PBS
and centrifuged at 4 °C at 900 × g for 4 min. The pellet was re-
suspended in buffer containing 10 mM HEPES (pH 7.4), 5 mM EGTA,
1 mM EDTA and 0.32 M sucrose and homogenized with a glass-Teﬂon
homogeniser at 4 °C. The homogenate was centrifuged at 20,000 × g
for 20 min and the membrane pellet was re-suspended in 50 mM
HEPES (pH 7.4) to obtain 5 mg/ml protein solution which was stored
at −80 °C until using. Binding assays were performed in 96-well,
round-bottomed microtiter plates with total reaction volumes of
200 μl, containing 20 μg of membrane preparation and different
concentrations of [3H]-5-HT with or without 10 μM of non-labelled
serotonin in 50mM Tris–HCl (pH 7.5), 1 mM EDTA, 5mMEGTA, 2mM
MgCl, 1 mM ascorbate, 0.1% BSA and 100 μM GTP. The reaction mix
was incubated at 23 °C for 60 min and transferred to the Whatman
Hydrophilic GF/C Filter pre-soaked in 0.3% polyethyleneimine,washed with approximately 4 ml/well with an ice-cold buffer
containing 50 mM Tris–HCl (pH 7.0) and 2 mM MgCl. The ﬁlters
were dried and counted in a Top-Count liquid scintillation counter
(Packard). Protein concentration was determined using the bicinch-
oninic acid (BCA) reagent system (Sigma).
2.9. Data analysis
The dose–response curves were ﬁtted by the equation y=(ymax-
ymin)/(1+(x/EC50)nH)+ymin, where EC50 is the concentration of
agonist producing a response equal to 50% of the maximum, ymax
and ymin correspond to the maximal and minimal values and nH to
the Hill coefﬁcient, by using Origin7 (OriginLab Corporation, MA)
software. Ratio of the receptor population in the non-active state
(R) versus this in the active state (R⁎) was calculated based on the
two-state model as described by Claeysen and co-workers [27].
3. Results
3.1. Palmitoylation of the 5-HT7(a) receptor
To analyze the post-translational modiﬁcation of the 5-HT7(a)
receptor, the receptor was tagged with a myc-epitope at its N-
terminus and expressed in insect Sf.9 cells using a recombinant
baculovirus system. Immunoblot analysis revealed a protein band
with molecular weight of approximately 46 kDa, which corresponded
to the predicted molecular mass of the 5-HT7(a) receptor (Fig. 1A).
Such speciﬁc bands were absent in non-infected Sf.9 cells or in cells
infected with the wild-type baculovirus.
To examine receptor acylation, Sf.9 cells infected with recombi-
nant or wild-type baculoviruses were labelled with [3H]-palmitate,
followed by immunoprecipitation, SDS–PAGE and ﬂuorography. The
ﬂuorogram demonstrated that the 5-HT7(a) receptor effectively
incorporated [3H]-palmitate (Fig. 1A). The identity of the protein-
bound fatty acids in 5-HT7(a) receptors was proven by the fatty acid
analysis. Fatty acids were hydrolyzed from gel-puriﬁed 5-HT7(a)
receptors and separated into the individual fatty acid species by thin
layer chromatography (TLC). Analysis of the TLC data revealed that
5-HT7(a) receptors contained predominantly palmitic acid, with
traces (b3%) of myristic and stearic acids (Fig. 1B).
Next we analyzed the chemical nature of the fatty acid bound to
the 5-HT7(a) receptor in order to distinguish between amide- and
ester-type fatty acid linkages. In contrast to the amide bond linkage,
the thioester and hydroxyester linkages are sensitive to the presence
of β-mercaptoethanol. Moreover, the thioester bond can be distin-
guished from hydroxyester by its sensitivity to treatment with
hydroxylamine [19]. As shown in Fig. 2A, the [3H]-palmitate-derived
radioactivity was sensitive to a treatment with increasing concentra-
tions of β-mercaptoethanol. Moreover, a treatment of [3H]-palmitate-
labelled 5-HT7(a) receptor with neutral hydroxylamine resulted in a
complete cleavage of the label from the protein (Fig. 2B). Such
sensitivity to neutral hydroxylamine and reducing agent demon-
strates that fatty acid is bound to the 5-HT7(a) receptor via thioester-
type linkage.
3.2. Agonist-mediated changes of 5-HT7(a) receptor palmitoylation
To test whether palmitoylation of the 5-HT7(a) receptor may be
regulated by its agonist, Sf.9 cells expressing receptors were labelled
with [3H]-palmitic acid for 60 min in the absence or presence of
increasing concentrations of serotonin. Fig. 3A shows that treatment
with agonist results in dose-dependent increase of [3H]-palmitate
incorporation into the receptor, while receptor synthesis was not
affected. The change in receptor-[3H]-palmitate labelling upon
serotonin stimulation was not due to general metabolic effects,
because the incorporation of Tran[35S]-label into total proteins was
Fig. 2. Sensitivity of receptor-bound fatty acid to β-mercaptoethanol and hydroxyl-
amine. (A) [3H]-palmitate-labelled 5-HT7(a) receptor was immunoprecipitated with
anti-myc antibodies and treated with non-reducing gel loading buffer or with the
same buffer containing 5%, 10% or 15% β-mercaptoethanol for 30 min at 37 °C prior
to SDS–PAGE and ﬂuorography. (B) Sf.9 cells expressing 5-HT7(a) receptor were labelled
with [3H]-palmitate, immunoprecipitated and subjected to SDS–PAGE. The gelwas treated
with 1 M Tris–HCl or 1 M hydroxylamine prior to ﬂuorography. The labelling with Tran
[35S]-labelwasusedas a expression control. Theﬂuorograms shownare a representative of
at least three independent experiments. The exposure time was 10 days.
Fig. 1. Palmitoylation of the 5-HT7(a) receptor in insect cells. (A) Sf.9 cells infected with
a baculovirus encoding for recombinant, myc-tagged 5-HT7(a) receptor or with a wild-
type baculovirus (Bac) were labelled for 2 h either with Tran[35S]-label (left panel) or
with [3H]-palmitate (right panel). Cell lysates were subjected to immunoprecipitation
with anti-myc antibodies followed by SDS–PAGE and ﬂuorography. The exposure time
was 1 day for Tran[35S]-label and 7 days for [3H]-palmitate labelling. The molecular
weight marker is indicated between the panels. Representative of at least three
independent experiments is shown. (B) The 5-HT7(a) receptor labelled with [3H]-
palmitate was immunoprecipitated and then subjected to the fatty acid analysis by thin
layer chromatography (TLC). The ﬂuorogram of the TLC plate was analyzed with Gel-
Pro Analyzer software. The mobility of authentic [3H]-palmitate, [3H]-stearate and [3H]-
myristate standards is indicated by arrows. Representative of three independent
experiments is shown.
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receptor palmitoylation upon agonist stimulation was receptor
speciﬁc, because it was blocked by application of highly selective
receptor antagonist SB269970 [28] and clozapine, whichwas reported
to be a potent 5-HT7 inverse agonist [29] (Fig. 3B).
To further exclude the inﬂuence of changes in receptor synthesis
upon palmitoylation, cells expressing receptor were labelled with [3H]-
palmitate or Tran[35S]-label in the presence or absence of protein
synthesis blocker cycloheximide. As shown in Fig. 3C, inhibition of
protein synthesis had no effect on the 5-HT7(a) receptor palmitoylation.
Moreover, palmitoylation the 5-HT7(a) receptor remained agonist-
promoted even in the presence of cycloheximide. These results show
that incorporation of palmitate into the 5-HT7(a) receptor is a post-
translational modiﬁcation and that previously synthesized proteins are
subject to repeated cycles of palmitoylation/depalmitoylation.
In order to obtain more detailed information about the dynamics
of receptor palmitoylation, Sf.9 cells expressing recombinant 5-HT7(a)
protein were treatedwith serotonin for different time intervals duringthe labelling procedure with [3H]-palmitate. As shown in Fig. 3D, the
intensity of radiolabel incorporation into the 5-HT7(a) receptor
without serotonin treatment increased steadily reﬂecting a basal
level of palmitoylation. When the kinetic of [3H]-palmitate incorpo-
ration was measured in the presence of serotonin, we obtained a
signiﬁcant increase in the efﬁciency of 5-HT7(a) receptor radiolabel-
ling over the whole incubation period (Fig. 3D). Taken together, these
data demonstrate that the 5-HT7(a) receptor is dynamically palmitoy-
lated in an agonist-dependent manner.
3.3. Identiﬁcation of potential acylation site(s) on the 5-HT7(a) receptor
In order to identify the potential palmitoylation site(s) within the
5-HT7(a) receptor, we constructed a series of mutant receptors in
which the C-terminal cysteine residues at positions 404 and 438/441
were substituted in different combinations by serines (Fig. 4A).
Immunoblot analysis revealed that the mutated receptors were
efﬁciently expressed along with the wild-type receptor (Fig. 4B).
We then quantiﬁed the level of palmitate incorporation for individual
mutants by densitometric analysis of ﬂuorograms after [3H]-palmitate
labelling in relation to the expression level (Fig. 4C). Of the three
cysteine residues in the C-terminal cytoplasmic domain of the
receptor, Cys404 is highly conserved among GPCRs and also
corresponds to the site that has been proposed to be palmitoylated.
A single mutation of this cysteine residue results in 28±13% decrease
in the degree of palmitoylation as compared with the wild-type.
Noteworthy that replacement of Cys438/441 that is located very close
to the C-terminal end of the receptor results in more prominent
decline of palmitoylation by 64±16%. Notably that substitution of all
Fig. 3.Modulation of the receptor palmitoylation by agonist. (A) Sf.9 cells expressing 5-
HT7(a) receptor were labelled with [3H]-palmitate for 60min in the absence (control) or
in the presence of increasing concentrations of serotonin. The receptor was
immunoprecipitated, separated on a 12% SDS-gel and subjected to ﬂuorography. The
right part shows the effect of serotonin treatment on receptor synthesis as assessed by
labelling with Tran[35S]-label. Representative of three independent experiments is
shown. (B) Sf.9 cells expressing 5-HT7(a) receptor were labelled with [3H]-palmitate for
60 min in the absence (control) or in the presence of serotonin (10 μM) applied either
alone or in combination with receptor antagonist SB269970 (SB) used at 10 μM or
inverse agonist clozapine used at 10 μM. The receptor was immunoprecipitated,
separated on a 12% SDS-gel and subjected to ﬂuorography. A representative of three
independent experiments is shown. (C) Insect cells expressing 5-HT7(a) receptor were
labelled for 60 min with [3H]-palmitate (upper panel) or Tran[35S]-label (low panel) in
the absence (−) or presence (+) of cycloheximide (50 μg/ml). In parallel, 1 μM
serotonin or vehicle (H2O) was added. Incorporation of radiolabel was detected by
immunoprecipitation followed by SDS–PAGE and ﬂuorography. A representative of
three independent experiments is shown. (D) Sf.9 cells expressing the 5-HT7(a) receptor
were incubated with [3H]-palmitate in the presence of either vehicle (H2O, control) or
1 μM serotonin for the time periods indicated. Receptor was immunoprecipitated,
resolved by SDS–PAGE and visualized by ﬂuorography. A representative ﬂuorogram of
three independent experiments is shown.
Fig. 4. C-terminal palmitoylation sites of the 5-HT7(a) receptor. (A) Amino acid sequence
of C-terminal domain of the 5-HT7(a) receptor wild-type and three substitution mutants
shown with a single-letter code. The serine residues substituting with the corresponding
cysteine residues are shown in bold. (B) The 5-HT7(a) receptor wild-type and substitution
mutants were expressed in Sf.9 cells, labelled with [3H]-palmitate and subjected to
immunoprecipitation, SDS–PAGE and ﬂuorography. The exposure time was 21 days for
[3H]-palmitate labeling (lower panel). Expression of thewild-type and acylation-deﬁcient
mutantwas analyzed by the immunobloting (IB, upper panel). Representative images are
shown. (C) The extent of palmitoylation for the substitution mutants was determined by
densitometry and calculated as ratio of [3H]-palmitate incorporation over the signal
detected by immunoblot. The value obtained for the wild-type 5-HT7(a) receptor was set
to 100 %. Data are presented as the means±S.E. (n=3).
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completely abolish [3H]-palmitic acid incorporation. Fig. 4B and C
demonstrates that after prolonged exposure this mutant shows low
(9±8% of the wild-type) but still detectable level of palmitoylation.
Thus, we conclude that although Cys404 and Cys438/441 represent
main palmitoylation sites of the 5-HT7(a) receptor, palmitoylation of
the receptor is not restricted to its C-terminus.3.4. Functional role of C-terminal palmitoylation: analysis in insect cells
To test for the functional signiﬁcance of C-terminal receptor
palmitoylation, we analyzed interaction of the 5-HT7(a) receptor with
different α-subunits of heterotrimeric G-protein by using the GTPγS
coupling assay [24]. First, Gα-subunits were co-expressed with the
Fig. 5. Role of palmitoylation for the coupling of the 5-HT7(a) receptor and G-proteins.
(A) Communication of the 5-HT7(a) receptor with different G-proteins. Membranes
were prepared from Sf.9 cells expressing Gβ1γ2- together with Gα-subunits as
indicated and then incubated with [35S]GTPγS in the presence of either vehicle (H2O) or
1 μM serotonin. Immunoprecipitations were performed with appropriate antibodies
directed against indicated Gα-subunits. Data points represent the means±S.E. from
at least three independent experiments. (B and C) Membranes were isolated from
Sf.9 cells co-expressing recombinant Gαs-subunit (B), Gα12-subunit (C) and Gβ1γ2-
subunits together with either the wild-type receptor or its acylation-deﬁcient
mutants. After incubation with [35S]GTPγS in the presence of vehicle (H2O) or 1 μM
serotonin, membranes were lysed and Gαs- or Gα12-subunits were immunopreci-
pitated with speciﬁc antibodies. The value obtained for the 5-HT7(a) receptor wild-
type after agonist stimulation was set to 100%. Data points represent the means±S.E.
from at least three independent experiments performed in duplicate. A statistically
signiﬁcant differences between non-treated wild-type and C404-S or C404/438/441-S
are noted (⁎, pb0.01).
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subunit was co-expressed with β1 and γ2-subunits), and agonist-
promoted binding of [35S]GTPγS to the Gα-subunit was accessed by
counting radioactivity directly after immunoprecipitation with ap-
propriate antibodies (Fig. 5A). When the wild-type 5-HT7(a) receptor
was co-expressed with Gαs or Gα12, wemeasured signiﬁcant increase
in [35S]GTPγS binding upon stimulation with serotonin. These results
conﬁrmed our previous data that the 5-HT7(a) receptor communicates
effectively not onlywith Gs- but also with G12-proteins [5]. In contrast,
there was no coupling after co-expression of the receptor with Gαi,
Gα13 or Gαq subunits (Fig. 5A).
We then tested the capacity of palmitoylation-deﬁcient receptor
mutants to couple to Gαs and Gα12 subunits. As shown in Fig. 5B,
stimulation of mutated receptors with serotonin resulted in a similar
increase of [35S]GTPγS binding to Gαs as in the wild-type. However,
the agonist-independent, constitutive receptor activity was signiﬁ-
cantly increased for the C404-S and C404/438/441-S mutants when
compared to the receptor wild-type (Fig. 5B). In contrast, agonist-Fig. 6. Serotonin-induced cAMP formation in COS-7 cells expressing 5-HT7(a) receptors.
(A) Intracellular cAMP level was measured at increasing concentrations of 5-HT in
transfected COS-7 cells as described in Materials and Methods. The agonist-
independent and serotonin-mediated changes of adenylyl cyclase stimulation are
shown as a percentage of cAMP accumulation measured in mock-transfected cells
(0.12±0.03% conversion of ATP to cAMP). Data points represent the means±S.E.
from three independent experiments performed in triplicate. (B) The effect of
serotonin (1 μM) or inverse receptor agonist clozapine (1 μM) on constitutive 5-HT7(a)
receptor activity was evaluated for wild-type and acylation-deﬁcient mutants. Levels
of cAMP accumulation were measured after 15-min incubation and expressed as a
percentage of cAMP accumulation in mock-transfected cells (basal). Each value is the
mean±S.E. of at least three independent experiments, each performed in triplicate. A
statistically signiﬁcant differences between non-treated wild-type and C404-S or
C404/438/441-S are noted (⁎, pb0.01).
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C438/441-S mutant was quite similar to that obtained in the wild-
type. These results indicate that proximal (Cys404) but not the distal
(Cys438/441) acylation site is selectively involved in modulation of
agonist-independent, Gs-mediated receptor activity.
In contrast to Gs-mediated signalling, the basal as well as agonist-
mediated coupling of the 5-HT7(a) receptor to the G12-protein was not
affected by replacement of C-terminal palmitoylation sites (Fig. 5C).3.5. Functional role of C-terminal palmitoylation: analysis in
mammalian cells
The experiments with insect cells demonstrated the possible
involvement of C-terminal palmitoylation in regulation of constitutive,
Gs-mediated receptor activity. Since the 5-HT7(a) receptor is naturally
expressed in vertebrates, we tested the functional role of receptor
palmitoylation in a mammalian cell system. As a model system we
used COS-7 cells that do not contain any detectable [3H]-5-HT binding
sites. As a functional readout we analyzed the ability of the wild-type
andmutant receptors to modulate an intracellular level of cAMP upon
agonist stimulation. To avoid artefacts resulting from over-expression,
we adjusted the total expression level for the wild-type and mutated
receptors to 1500–1600 fmol/mg protein, which allowed for a
quantitative analysis of results and for their physiological interpretation.
Expression of the wild-type and acylation-deﬁcient mutants of
5-HT7(a) receptor resulted in signiﬁcant increase of cAMP formation
upon stimulationwith serotonin in a dose-dependentmanner (Fig. 6A).
It is noteworthy that replacement of cysteine residue 404 (either alone
or in combination with cysteines 438/441) was accompanied by a
signiﬁcant increase in the receptor afﬁnity, and the EC50 values
obtained for these mutants were about 5 to 7 times lower than those
obtained for the wild-type and C438/441-S mutant (Table 1). We
also found more than a 5-fold increase in the agonist-independent
cAMP production for the C404-S and triple mutants as compared
with the wild-type receptor (Fig. 6B). In contrast, agonist-indepen-
dent cAMP production for the C438/441-S mutant was quite similar
to the wild-type. Noteworthy that application of the potent 5-HT7
inverse agonist clozapine resulted in signiﬁcant reduction of basal
constitutive activity by approximately 60% for all receptors tested
(Fig. 6B). The inverse agonism mediated by clozapine was receptor
speciﬁc, because this effect was overcome by parallel application of 5-
HT (data not shown).
Although the agonist-mediated maximal response was slightly
increased in acylation-deﬁcient mutants, the high basal activity
obtained for the C404-S and C404/438/441-S mutants leads to a
decrease in relative efﬁcacy of serotonin (10−6 M) to stimulate over
basal constitutive activity (Fig. 6B).
To further analyze the impact of C-terminal palmitoylation for the
constitutive activity of the 5-HT7(a), we compared KD values for wild-
type and mutated receptors. As shown in Table 1, the afﬁnity ofTable 1
Results of binding experiments and cAMP production for the wild-type and acylation-
deﬁcient 5-HT7(a) receptors.
WT C404-S C438/441-S C404/438/441-S
KD±S.E. (nM) 4.3±0.9 1.7±0.4⁎ 2.4±0.6 0.9±0.2⁎
EC50±S.E. (nM) 8.8±0.9 1.2±0.4⁎ 6.9±0.7 1.6±0.6⁎
Wild-type and mutant receptors were transiently transfected in COS-7 cells and used
for saturation (KD values) binding analysis. [3H]5-HT was used as a selective agonist.
EC50 values refer to the agonist concentration yielding 50% of the maximal activation.
Data are expressed as means±S.E. of at least four independent experiments. A
statistically signiﬁcant differences between wild-type and C404-S or C404/438/441-S
are noted.
⁎ pb0.01.serotonin for the C404-S and C404/438/441-S mutants was increased
as compared to thewild-type. Taken together, these data demonstrate
that C-terminal palmitoylation of the 5-HT7(a) receptor (particularly
at Cys404) contributes to the regulation of the receptor constitutive
activity.
4. Discussion
The covalent attachment of fatty acids to proteins is a
widespread post-translational modiﬁcation. Protein palmitoylation
represents a common lipid modiﬁcation of many signalling proteins,
including the growth-associated protein GAP-43 [30], α-subunits of
G-proteins [31,32], endothelial nitric oxide synthase [33], non-
receptor tyrosine kinases and numerous G-protein coupled recep-
tors [16,18]. Palmitoylation is unique among lipid modiﬁcations as it
is reversible and adjustable, and dynamic acylation has been
demonstrated for a number of signalling proteins. Regulated turn-
over of protein palmitoylation was ﬁrst reported for the peripheral
membrane protein p21-ras [34]. Similar results have been obtained
for other proteins involved in signal transduction, including α-
subunits of heterotrimeric G-protein [35,36] and e-NOS [37].
Meanwhile it is widely accepted that dynamic palmitoylation is
involved in the regulation of protein functions and signalling
[12,38,39]. Moreover, palmitoylation of several GPCRs, including
β2- and α2A-adrenergic, dopamine D1 and muscarinic acetylcholine
m2 receptors, has been shown to be regulated by the agonist [40-
44]. For the 5-HT4(a) receptor, we have recently demonstrated that
agonist stimulation increases the turnover rate of the receptor-
bound palmitate [19]. The present study demonstrates that
palmitoylation of the 5-HT7(a) receptor is also a dynamic process
which can be modiﬁed by agonists. Although the detailed
mechanism involved in such regulation of palmitoylation/depalmi-
toylation cycles of the 5-HT7(a) receptor is still unknown, our data
strongly suggest that the biological activation of the receptor does
enhance the palmitate exchange on this polypeptide. Dynamic
palmitoylation, however, seems to not be a general feature of
acylated GPCRs. We have recently demonstrated that palmitoylation
of another member of the serotonin receptor family, the 5-HT1A
receptor, reveals a stable modiﬁcation that is independent of agonist
stimulation [20].
To clarify the structural requirements and to study the speciﬁc
biological functions of dynamic palmitoylation of the 5-HT7(a)
receptor, we generated series of acylation-deﬁcient mutants. From
analysis of the primary structure of acylated GPCRs, it is known that
C-terminal cysteine residues located in close proximity to the
plasma membrane represent most common targets for palmitic acid
attachment [18]. The 5-HT7(a) receptor contains three such cysteine
residues within its C-terminus: Cys404 and cysteine cluster formed
by Cys438/441. Our results demonstrate that all these cysteine
residues can be modiﬁed by palmitate. While palmitoylation of the
conserved cysteine residue 404 is consistent with the general view
of the location of GPCR's acylation sites, cysteine residues 438/441
located very close to the C-terminal end of the receptor represent
unexpected palmitoylation sites. Although several palmitoylated
GPCRs (e.g., vasopressin V2, endothelin B, LH/hCG and β2-
adrenergic receptors) also possess multiple cysteine residues within
their cytoplasmic C-terminal domains, only those cysteine residues
localized in positions up to 14 amino acids from the membrane
border towards the cytoplasmic tail were found to serve as
functional acylation sites [45-48]. The existence of an additional
acylation site located distant from the plasma membrane has been
previously shown only for the 5-HT4(a) receptor. In this case we
demonstrated palmitoylation of Cys386, which is positioned 70
amino acids away from the plasma membrane border [22].
It is also notable that although C-terminal Cys404 and Cys438/441
represent main palmitoylation sites responsible for the attachment of
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receptor is not restricted to its C-terminus. The 5-HT7(a) receptor
contains 13 cysteine residueswithin its amino acid sequence in addition
to the three cysteines located within the cystoplasmic C-terminus.
Only three of these cysteines are located at the intracellular face of
receptor and, therefore,mayrepresentadditional acylation site(s). These
include Cys110, Cys201 and Cys305 resided in the ﬁrst transmembrane
domain and in the second and third intracellular loops, respectively.
Further experimentation will be necessary to validate the role of these
cysteine residues in the receptor palmitoylation.
Receptor acylation at different receptor–G-protein interfaces has
been shown to play greatly different functional roles, suggesting that
there is not a common function applicable to all sorts of GPCRs [17,18].
Therefore, studies of palmitoylation functions are necessary for each
individual receptor in order to understand its signalling mechanism.
Analysis of the C-terminal acylation-deﬁcient mutants of the 5-HT7(a)
receptor revealed that palmitoylation does not inﬂuence agonist-
mediated receptor coupling with Gs- and G12-proteins. However,
when the agonist-independent 5-HT7(a) receptor activity was ana-
lyzed, we found that mutation of the proximal palmitoylation site
Cys404-Ser (either alone or in combination with Cys438/441-Ser)
signiﬁcantly increases Gs- but not G12-mediated constitutive receptor
activity. Constitutive activity has been observed for more than 60
GPCRs and implies the capacity of receptors to convert from the
inactive (R) to the active (R⁎) form in the absence of agonist [49-51].
The constitutive activity of a native receptor is an important
pharmacological characteristic because this may explain part of its
physiological and also pathological behavior, as well as the effect of
drugs classiﬁed as inverse agonists [52]. Although constitutive activity
has been observed for a wide variety of GPCRs, molecular constraints
involved in the regulation of receptor constitutive activity remain
poorly understood. Depending on the GPCR analyzed, it has been
suggested that speciﬁc sequences within the intracellular loop i3 andFig. 7. Hypothetical model for regulation of receptor activity by dynamic palmitoylation.
populations of 5-HT7(a) receptor: population with two (A), one small (D), one large (B) or no
every conformation could be changed to one of the remaining three forms by basal or agonis
for Gs-mediated signalling.extracellular loop e2, as well as conserved hydrogen bond network
and rotamer toggle switch may be essential for the isomerization of
receptors from the R to the R⁎ form [51]. We have recently
demonstrated that agonist-independent activity of the 5-HT4(a)
receptor is regulated by its dynamic palmitoylation. In combination
with the present study, this suggests that palmitoylation represents
an additional important feature regulating constitutive receptor
activity. Moreover, in case of the 5-HT7(a) receptor, which is coupled
to both Gs- and G12-proteins, dynamic palmitoylation can also
represent a molecular mechanism responsible for selective Gs- or
G12-mediated signaling. Such regulatory effects of 5-HT7 palmitoyla-
tion may also be relevant in other species and in particular in humans.
Indeed, the proximal C-terminal cysteine residue is highly conserved
among all 5-HT7 receptor isoforms, including human splicing variants
5-HT7(a), 5-HT7(b) and 5-HT7(d) [53]. The human receptor isoform 5-
HT7(a) also possesses distal cysteine residue Cys381, which represents
second potential acylation site.
What should be a possible mechanism, by which palmitoylation
regulates constitutive activity of the 5-HT7 receptors? One possibility
is that by providing a lipophilic membrane anchor palmitoylation is
responsible for formation of additional ﬂexible C-terminal intracellu-
lar loop(s) involved either in the receptor/G-protein recognition
process or in G-protein binding and/or receptor-mediated G-protein
activation (Fig. 7). Palmitoylation of all C-terminal cysteines will
result in formation of two additional intracellular loops (Fig. 7A). This
conformation together with conformation where only Cys404 is
palmitoylated (Fig. 7D) may be responsible for the low basal level of
agonist-independent activity. Depalmitoylation of Cys404 alone or in
combination with Cys438/441 could result in formation of a single
large intracellular loop or in non-anchored C-terminus, respectively
(Fig. 7B and C). Functionally, these conformations may lead to a
signiﬁcant increase of constitutive receptor activity. Such model in
combination with dynamic receptor palmitoylation can explain theDepending on the number of palmitoylated cysteines we suggest existence of four
(D) intracellular C-terminal loops. These populations exist in dynamic equilibrium, and
t-promoted palmitate turnover. Asterisk shows the receptor in constitutive active form
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receptors in neurons [54-57]. Indeed, dynamic receptor palmitoyla-
tion implies that at any given point populations of differently
palmitoylated receptors are present in the cell, also including the
forms with a high constitutive activity (Fig. 7B and C).Acknowledgments
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